121 related articles for article (PubMed ID: 33063470)
1. Novel 5-point 18-FDG-PET/CT visual scoring system for assessing treatment response in patients with oesophageal or gastro-oesophageal junction carcinoma.
Cong E; Oar AJ; Lee MT; Chicco A; Lin M; Yap J; Lin P; Ho Shon I
J Med Imaging Radiat Oncol; 2021 Feb; 65(1):23-37. PubMed ID: 33063470
[TBL] [Abstract][Full Text] [Related]
2. Fluorine-18 fluorodeoxyglucose positron emission tomography in the preoperative staging of thoracic oesophageal and gastro-oesophageal junction cancer: a prospective study.
Katsoulis IE; Wong WL; Mattheou AK; Damani N; Chambers J; Livingstone JI
Int J Surg; 2007 Dec; 5(6):399-403. PubMed ID: 17631431
[TBL] [Abstract][Full Text] [Related]
3. Significance of baseline FDG-PET/CT scan as a method of staging regional lymph nodes in patients with operable distal oesophageal or gastroesophageal junction adenocarcinoma.
Papaxoinis G; Weaver JMJ; Khoja L; Patrao A; Stamatopoulou S; Alchawaf A; Owen-Holt V; Germetaki T; Kordatou Z; Mansoor W
Acta Oncol; 2017 Sep; 56(9):1224-1232. PubMed ID: 28524708
[TBL] [Abstract][Full Text] [Related]
4. Laparoscopy, computerised tomography and fluorodeoxyglucose positron emission tomography in the management of gastric and gastro-oesophageal junction cancers.
Mirza A; Galloway S
Surg Endosc; 2016 Jul; 30(7):2690-6. PubMed ID: 26487234
[TBL] [Abstract][Full Text] [Related]
5.
Linder G; Korsavidou-Hult N; Bjerner T; Ahlström H; Hedberg J
Clin Radiol; 2019 Sep; 74(9):718-725. PubMed ID: 31221468
[TBL] [Abstract][Full Text] [Related]
6. Role of PET/PET CT in the staging and restaging of thoracic oesophageal cancer and gastro-oesophageal cancer: a literature review.
Wong WL; Chambers RJ
Abdom Imaging; 2008; 33(2):183-90. PubMed ID: 17619927
[TBL] [Abstract][Full Text] [Related]
7. Serial imaging using [18F]Fluorodeoxyglucose positron emission tomography and histopathologic assessment in predicting survival in a population of surgically resectable distal oesophageal and gastric adenocarcinoma following neoadjuvant therapy.
Manoharan V; Lee S; Chong S; Yap J; Coupe N; Wilson R; Merrett N; Ng W; Lin M
Ann Nucl Med; 2017 May; 31(4):315-323. PubMed ID: 28299585
[TBL] [Abstract][Full Text] [Related]
8. Is there a role for PET/CT with esophagogastric junction adenocarcinoma?
Fuster D; Mayoral M; Rubello D; Pineda E; Fernández-Esparrach G; Pagès M; Colletti PM; Pons F
Clin Nucl Med; 2015 Mar; 40(3):e201-7. PubMed ID: 25546207
[TBL] [Abstract][Full Text] [Related]
9. Temporal validation of metabolic nodal response of esophageal cancer to neoadjuvant chemotherapy as an independent predictor of unresectable disease, survival, and recurrence.
Findlay JM; Dickson E; Fiorani C; Bradley KM; Mukherjee S; Gillies RS; Maynard ND; Middleton MR
Eur Radiol; 2019 Dec; 29(12):6717-6727. PubMed ID: 31278574
[TBL] [Abstract][Full Text] [Related]
10. The correlation between molecular pathological profiles and metabolic parameters of
Song J; Li Z; Chen P; Zhou N; Zhang Y; Yang Z; Wang X
Abdom Radiol (NY); 2020 Feb; 45(2):312-321. PubMed ID: 31111196
[TBL] [Abstract][Full Text] [Related]
11. [Fluorodeoxyglucose-positron emission tomography in carcinoma of the esophagogastric junction].
Wang T; Sun YE; Chu XY; Tian JH; Liu Y
Zhonghua Wai Ke Za Zhi; 2004 Jun; 42(11):651-3. PubMed ID: 15329251
[TBL] [Abstract][Full Text] [Related]
12. "Sentinel lymph node imaging with sequential SPECT/CT lymphoscintigraphy before and after neoadjuvant chemoradiotherapy in patients with cancer of the oesophagus or gastro-oesophageal junction - a pilot study".
Gabrielson S; Tsai JA; Celebioglu F; Nilsson M; Rouvelas I; Lindblad M; Bjäreback A; Tomson A; Axelsson R
Cancer Imaging; 2018 Dec; 18(1):53. PubMed ID: 30563571
[TBL] [Abstract][Full Text] [Related]
13. Fluorodeoxyglucose-positron emission tomography in adenocarcinomas of the distal esophagus and cardia.
Ott K; Weber WA; Fink U; Helmberger H; Becker K; Stein HJ; Müller J; Schwaiger M; Siewert JR
World J Surg; 2003 Sep; 27(9):1035-9. PubMed ID: 12917760
[TBL] [Abstract][Full Text] [Related]
14. Pragmatic staging of oesophageal cancer using decision theory involving selective endoscopic ultrasonography, PET and laparoscopy.
Findlay JM; Bradley KM; Maile EJ; Braden B; Maw J; Phillips-Hughes J; Gillies RS; Maynard ND; Middleton MR
Br J Surg; 2015 Nov; 102(12):1488-99. PubMed ID: 26458070
[TBL] [Abstract][Full Text] [Related]
15. Dual-time point
Park S; Paeng JC; Kang CH; Cheon GJ; Kang KW; Chung JK; Lee DS
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1317-1328. PubMed ID: 29502309
[TBL] [Abstract][Full Text] [Related]
16. Complete pathological response (pCR) in gastroesophageal cancer: Correlation with metabolic response.
Cabral F; Cruz A; Casaca R; Monteiro C; Ramos P; Pedro C; Brandão F; Fonseca R; Ratão P; Salgado L; Pinto I; Abecasis N
Cancer Radiother; 2020 Dec; 24(8):834-841. PubMed ID: 33191120
[TBL] [Abstract][Full Text] [Related]
17. Influence of Baseline Positron Emission Tomography in Metastatic Gastroesophageal Cancer on Survival and Response to Therapy.
Abdelhakeem A; Patnana M; Wang X; Rogers JE; Murphy MB; Sagebiel T; Ikoma N; Badgwell BD; Trail A; Estrella JS; Lu Y; Devine C; Ajani JA
Oncology; 2021; 99(10):659-664. PubMed ID: 34352788
[TBL] [Abstract][Full Text] [Related]
18. Value of complete metabolic response by (18)F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy.
Kim MK; Ryu JS; Kim SB; Ahn JH; Kim SY; Park SI; Kim YH; Song HY; Shin JH; Jung HY; Lee GH; Choi KD; Cho KJ; Kim JH
Eur J Cancer; 2007 Jun; 43(9):1385-91. PubMed ID: 17512192
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic performance of
Chaput A; Robin P; Podeur F; Ollivier M; Keromnes N; Tissot V; Nonent M; Salaün PY; Rousset J; Abgral R
Laryngoscope; 2018 Feb; 128(2):378-385. PubMed ID: 28600822
[TBL] [Abstract][Full Text] [Related]
20. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer.
Flamen P; Van Cutsem E; Lerut A; Cambier JP; Haustermans K; Bormans G; De Leyn P; Van Raemdonck D; De Wever W; Ectors N; Maes A; Mortelmans L
Ann Oncol; 2002 Mar; 13(3):361-8. PubMed ID: 11996465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
